Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
547 articles with Horizon Therapeutics
-
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences - Dec 23, 2021
12/23/2021
Horizon Therapeutics plc announced that the Company will participate in the following upcoming virtual investor conferences.
-
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
12/16/2021
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine’s unique discovery platform.
-
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
-
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List - Dec 02, 2021
12/2/2021
Horizon Therapeutics plc announced that it has been named to Great Place to Work’s 2021 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents.
-
Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
12/1/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced $140,000 in scholarships to help economically disadvantaged students from Trinity College Dublin and Waterford Institute of Technology cover their non-tuition expenses.
-
New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
11/22/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that a new post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 pivotal trial has been published in Multiple Sclerosis and Related Disorders showing that prior rituximab exposure did not impact the efficacy of UPLIZNA, and that UPLIZNA demonstrated comparable efficacy to trial participants without prior exposure to rituximab.
-
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
11/15/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its support of Thyroid Eye Disease (TED) Awareness Week through the launch of new educational resources designed to help people IdentifEYE TED, with a focus on symptoms, risks and where to seek care.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
11/12/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced findings of a real-world adherence analysis of TEPEZZA for the treatment of TED at the American Academy of Ophthalmology Annual Meeting (AAO 2021).
-
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
11/9/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis (also known as scleroderma).
-
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Horizon Therapeutics plc announced that the Company will participate in the following upcoming conferences.
-
Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
11/5/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune’s Top Workplaces 2021 , ranking No. 5 out of 75 other midsize companies in the Chicago area.
-
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
11/4/2021
Results from PROTECT Trial Evaluating KRYSTEXXA ® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
-
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
-
Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
11/3/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced record third-quarter 2021 financial results and increased both its full-year 2021 net sales and adjusted EBITDA guidance.
-
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
11/3/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced Paul Hoelscher, executive vice president, chief financial officer, will retire effective May 16, 2022, and continue as an advisor to the Company through May 2023. Aaron Cox, who was named executive vice president, finance, will succeed Mr. Hoelscher.
-
New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
11/1/2021
Horizon Therapeutics plc announced presentations on results from a new survey of practicing rheumatologists suggesting the presence of negative gout stigma surrounding causality and management of gout.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
10/25/2021
Horizon Therapeutics plc (Nasdaq: HZNP) today announced topline results met the primary endpoint, showing a significant increase in efficacy using KRYSTEXXA